In 2023, the global landscape of intramural R&D expenditure in medical and health sciences highlighted South Korea leading with $8.5 billion PPP, indicating substantial investment growth with a 12.91% year-over-year increase. Poland stood out with the highest percentage increase of 15.85%, followed by Slovakia at 15.63%. Taiwan, Singapore, and Russia maintained moderate growth rates, signaling stable investment in this sector. Conversely, countries like the Czech Republic and Latvia showed minimal growth. These variations underscore diverse prioritization and economic capabilities in R&D investments across countries.
Looking ahead, emerging technologies, demographic shifts, and global health challenges are likely to drive increased R&D expenditure in medical sciences. Countries with innovative ecosystems and significant investments in biotechnology and healthcare digitalization are expected to maintain or even accelerate their growth in this sector. Additionally, collaborations and partnerships on a global scale could play a critical role in shaping the future trends of R&D spending.
Top countries in Total Intramural Expenditure on R&D in Medical and Health Sciences by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 South Korea | 8,500 | 2023 | +7.99% | +12.91% | View data |
| 2 | 2 Taiwan | 3,530 | 2023 | +3.92% | +4.73% | View data |
| 3 | 3 Poland | 3,350 | 2023 | +11.28% | +15.85% | View data |
| 4 | 4 Singapore | 2,770 | 2023 | +4.02% | +8.01% | View data |
| 5 | 5 Russia | 2,090 | 2023 | +3.36% | +4.27% | View data |
| 6 | 6 Portugal | 913.76 | 2023 | +3.87% | +7.91% | View data |
| 7 | 7 Czech Republic | 600.4 | 2023 | +3.11% | +1.74% | View data |
| 8 | 8 Hungary | 356.62 | 2023 | +2.52% | +4.61% | View data |
| 9 | 9 Slovenia | 311.43 | 2023 | +2.54% | +5.18% | View data |
| 10 | 10 Chile | 221.73 | 2023 | +2.71% | +2.69% | View data |
